Haisco Pharmaceutical Group (002653) Q2 2024 earnings summary

Executive summary

• Achieved revenue of ¥1.687 billion in H1 2024, up 23.14% year-over-year; net profit attributable to shareholders was ¥164.72 million, up 119.40% year-over-year.

• Core innovative drugs (环泊酚, 苯磺酸克利加巴林, 考格列汀) drove rapid growth and market expansion.

• R&D pipeline robust with 44 projects, including 24 innovative drugs; multiple new approvals and clinical advancements.

Financial highlights

• Operating income: ¥1.687 billion, up 23.14% year-over-year.

• Net profit attributable to shareholders: ¥164.72 million, up 119.40% year-over-year.

• Operating cash flow: ¥110.45 million, up 99.75% year-over-year.

• Gross margin for pharmaceutical segment: 72.13%.

• Basic and diluted EPS: ¥0.1481, up 118.11% year-over-year.

Outlook and guidance

• Plans to accelerate clinical trials for key innovative drugs in anesthesia, pain, metabolism, oncology, and respiratory fields.

• Focus on expanding hospital and retail channels for new drugs, aiming for rapid market penetration.

• Continued investment in R&D and production capacity to support pipeline and commercialization.